Breaking Through the Investment Gap: Mark Andrews Discusses British Patient Capital's Life Sciences Fund

Andrii: Can you tell us about yourself and your journey into the life sciences?

Mark: After training for a number of years in Biological Sciences at UK universities, I started my career in the mid-1990s working in academic research. I worked across several laboratories and research institutions in both the UK and Europe in the fields of oncology, immunology and transplantation medicine. After a number of years working in labs, I moved into the investment side of life sciences working as a life science venture capital investor at international investment fund managers. During this period, I held several non-executive director roles around the world supporting start-ups in the life sciences sector as they develop new drugs and therapies to improve the lives of patients. 

Immediately prior to joining BPC, I worked in the corporate advisory space where I continued to support life science companies from young start-ups through to large multinational corporations complete deals including M&A deals, fundraising and licensing deals. I joined British Patient Capital in 2022 and now work as an Investment Director overseeing the life sciences fund investments of the business. Leveraging my experience in the sector and across the investment cycle, I now manage British Patient Capital’s investments in life sciences funds that are enabling the most promising later-stage UK companies to scale.

Andrii: It would be interesting to learn more about British Patient Capital’s work. What is the investment strategy, and what are the specific biotech/healthcare sectors you may be prioritizing based on the fund’s vision?